Cdk6 Inhibitors
Items 1 to 10 of 19 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol acts as a potent inhibitor of Cdk6, characterized by its ability to disrupt the ATP-binding site through specific hydrogen bonding and hydrophobic interactions. This compound alters the conformational landscape of Cdk6, leading to a decrease in kinase activity. Its unique structural features enable selective targeting of the enzyme, influencing the phosphorylation cascade and modulating cell cycle progression. The compound's kinetic profile reveals a rapid onset of inhibition, underscoring its dynamic interaction with the kinase. | ||||||
Fascaplysin | 114719-57-2 | sc-221607 sc-221607A | 1 mg 5 mg | $64.00 $246.00 | 5 | |
Fascaplysin is a selective inhibitor of Cdk6, distinguished by its unique binding affinity that stabilizes the inactive conformation of the kinase. This compound engages in specific π-π stacking interactions and hydrophobic contacts, effectively blocking substrate access. Its distinct molecular architecture facilitates a prolonged inhibitory effect, altering the enzyme's catalytic efficiency. The compound's interaction kinetics suggest a slow dissociation rate, enhancing its potential for sustained modulation of cell cycle dynamics. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of Cdk4 and Cdk6. It specifically binds to these cyclin-dependent kinases, preventing their activation and subsequent phosphorylation of retinoblastoma protein (Rb), leading to cell cycle arrest in the G1 phase. | ||||||
Purvalanol B | 212844-54-7 | sc-361300 sc-361300A | 10 mg 50 mg | $199.00 $846.00 | ||
Purvalanol B is a selective inhibitor of Cdk6, characterized by its ability to disrupt the enzyme's ATP-binding site through unique hydrogen bonding and van der Waals interactions. This compound exhibits a distinct conformational rigidity that prevents the kinase from adopting an active state, thereby impeding its phosphorylation activity. The kinetic profile indicates a rapid association with Cdk6, leading to effective inhibition of cell cycle progression through targeted disruption of regulatory pathways. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib is a potent inhibitor of Cdk4 and Cdk6. By blocking the activity of these kinases, Ribociclib impedes the phosphorylation of Rb, resulting in cell cycle arrest and inhibition of cancer cell proliferation. | ||||||
Fisetin | 528-48-3 | sc-276440 sc-276440A sc-276440B sc-276440C sc-276440D | 50 mg 100 mg 500 mg 1 g 100 g | $52.00 $79.00 $104.00 $156.00 $2913.00 | 7 | |
Fisetin acts as a modulator of Cdk6 by engaging in specific interactions that alter the enzyme's conformation. Its unique structure allows for selective binding, influencing the enzyme's catalytic activity through steric hindrance and electrostatic interactions. This compound exhibits a notable ability to stabilize inactive forms of Cdk6, thereby affecting downstream signaling pathways. The reaction kinetics reveal a gradual dissociation, suggesting a prolonged regulatory effect on cellular processes. | ||||||
R(-) Iberin | 505-44-2 | sc-364348 sc-364348A | 10 mg 50 mg | $336.00 $1120.00 | 1 | |
R(-) Iberin functions as a selective inhibitor of Cdk6, characterized by its ability to disrupt the enzyme's active site through unique hydrogen bonding and hydrophobic interactions. This compound exhibits a distinct binding affinity that alters the enzyme's dynamics, leading to a reduction in phosphorylation activity. Its kinetic profile indicates a rapid association with Cdk6, followed by a slower dissociation, which may enhance its regulatory impact on cell cycle progression. | ||||||
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine Methanesulfonate | 1231930-82-7 | sc-496536 | 2.5 mg | $398.00 | ||
Abemaciclib is a selective inhibitor of Cdk4 and Cdk6. It hinders their kinase activity, leading to the inhibition of Rb phosphorylation and cell cycle arrest in the G1 phase. | ||||||
Cdk4/6 Inhibitor IV | 359886-84-3 | sc-203874 | 5 mg | $265.00 | 3 | |
Cdk4/6 Inhibitor IV is a potent modulator of Cdk6, showcasing a unique mechanism of action through specific allosteric interactions that stabilize the inactive conformation of the enzyme. This compound exhibits a remarkable selectivity, influencing the conformational landscape of Cdk6 and effectively impeding its kinase activity. The inhibitor's reaction kinetics reveal a fast initial binding phase, followed by a prolonged engagement, which may significantly alter downstream signaling pathways. | ||||||
Cdk/Crk Inhibitor | 784211-09-2 | sc-203872 | 1 mg | $290.00 | ||
Cdk/Crk Inhibitor operates as a selective antagonist of Cdk6, characterized by its ability to disrupt critical protein-protein interactions essential for cell cycle progression. This compound engages in unique hydrogen bonding and hydrophobic interactions, leading to a conformational shift that inhibits substrate access. Its kinetic profile indicates a slow dissociation rate, allowing for sustained modulation of Cdk6 activity, thereby influencing cellular signaling dynamics and regulatory networks. | ||||||